Litcius/Paper detail

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar, Anna F. Farago, Catherine M. Albert, Kristoffer Staal Rohrberg, Cornelis M. van Tilburg, Ramamoorthy Nagasubramanian, Jordan Berlin, Noah Federman, Leo Mascarenhas, Birgit Geoerger, Afshin Dowlati, Alberto S. Pappo, Stefan Bielack, François Doz, Ray McDermott, Jyoti D. Patel, Russell J. Schilder, Makoto Tahara, Stefan M. Pfister, Olaf Witt, Marc Ladanyi, Erin R. Rudzinski, Shivani Nanda, Barrett H. Childs, Theodore W. Laetsch, David M. Hyman, Alexander Drilon

2020The Lancet Oncology995 citationsDOIOpen Access PDF

Topics & Concepts

Trk receptorMedicineInternal medicinePooled analysisPopulationClinical endpointClinical trialOncologyPediatricsSurgeryConfidence intervalReceptorNeurotrophinEnvironmental healthLung Cancer Treatments and MutationsChromatin Remodeling and CancerMelanoma and MAPK Pathways
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials | Litcius